• Legend Biotech will present updated CARVYKTI and investigational cell therapy findings at ASH, December 12-15, 2026, in New Orleans.
• CARTITUDE-4 subgroup findings showed durable disease control with CARVYKTI in treatment-resistant multiple myeloma as early as second-line treatment.
• CITADEL findings showed a lower rate of treatment-associated parkinsonism with a preemptive steroid strategy compared with historical data.
• Investigational in vivo CAR-T therapy LB2501 produced complete responses in all eight patients treated at the second dose level.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-007100), on November 04, 2026, and is solely responsible for the information contained therein.